BOOK
Adjunctive Technologies in the Management of Head and Neck Pathology, An Issue of Oral and Maxillofacial Clinics of North America, E-Book
(2014)
Additional Information
Book Details
Abstract
Adjunctive Technologies in the Management of Head and Neck Pathology, An Issue of Oral and Maxillofacial Clinics of North America, E-Book
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Cover | ||
Adjunctive Technologies in the Management of Head and\rNeck Pathology | i | ||
copyright\r | ii | ||
Contributors | iii | ||
Contents | v | ||
Oral And Maxillofacial Surgery\rClinics Of North America\r | viii | ||
Preface\r | ix | ||
Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis | 123 | ||
Key points | 123 | ||
Changing epidemiology of head and neck cancer | 123 | ||
Incidence | 123 | ||
Risk factors for HNSCC | 124 | ||
Tobacco, Alcohol, Pan | 124 | ||
HPV | 124 | ||
Other Contributing Factors | 125 | ||
Diseases and syndromes associated with increased risk for HNSCC | 125 | ||
Plummer-Vinson | 125 | ||
Fanconi Anemia and Dyskeratosis Congenita | 125 | ||
Age, sex, and race predilection of HNSCC | 125 | ||
Anatomic sites of HNSCC | 126 | ||
Tongue | 126 | ||
Floor of Mouth | 126 | ||
Precursor lesions of HNSCC | 126 | ||
Premalignant Lesion | 126 | ||
Premalignant Condition | 126 | ||
Leukoplakia | 126 | ||
Proliferative Verrucous Leukoplakia | 128 | ||
Erythroplakia | 129 | ||
Oral Submucous Fibrosis | 129 | ||
Oral Lichen Planus | 129 | ||
Autofluorescence tissue-imaging devices for screening of HNSCC and its precursors | 130 | ||
Oral epithelial dysplasia | 131 | ||
Prediction of prognosis, treatment response, and survival in head and neck cancer | 133 | ||
Biopsy Evaluation | 133 | ||
Histologic Subtypes of SCC | 133 | ||
Conventional/keratinizing SCC | 133 | ||
HPV-associated SCC (HPV+ OPSCC) | 133 | ||
Verrucous carcinoma | 134 | ||
Papillary squamous carcinoma | 134 | ||
Basaloid squamous carcinoma | 134 | ||
Sarcomatoid squamous carcinoma (spindled cell carcinoma) | 136 | ||
Histopathology prognosticators in SCC | 136 | ||
Margins | 137 | ||
Lymph Node Metastases and Extracapsular Extension | 137 | ||
Tumor staging | 138 | ||
Diagnostically relevant immunohistochemical stains for head and neck pathology | 138 | ||
Immunohistochemistry | 138 | ||
Makers for Infections | 138 | ||
Prognostic biomarkers for HNSCC | 138 | ||
HPV and p16 | 138 | ||
Molecular alterations in HNSCC | 139 | ||
Tp53 and EGFR | 139 | ||
Acknowledgments | 139 | ||
References | 139 | ||
Use of Porous Space Maintainers in Staged Mandibular Reconstruction | 143 | ||
Key points | 143 | ||
Introduction | 143 | ||
Clinical challenge | 143 | ||
Technical innovations | 144 | ||
Advantages of porous space maintainers | 144 | ||
Implant fabrication | 145 | ||
Case series | 145 | ||
Clinical outcomes | 146 | ||
Summary | 148 | ||
References | 148 | ||
Pitfalls in Determining Head and Neck Surgical Margins | 151 | ||
Key points | 151 | ||
Introduction | 151 | ||
Historical perspective | 151 | ||
Oral cavity cancer epidemiology | 152 | ||
Margin assessment | 152 | ||
Margin Measurements | 152 | ||
Anatomic and Histologic Margins | 152 | ||
Meeting with Pathologist: Tumor Mapping | 154 | ||
Pathologic Assessment of Margins: Techniques | 155 | ||
Bone Margins | 155 | ||
Tissue Shrinkage | 156 | ||
Excision Method | 157 | ||
Good Margins | 157 | ||
Margin Reporting | 157 | ||
Therapeutic implications of positive margins | 158 | ||
Future directions | 159 | ||
Summary | 160 | ||
References | 160 | ||
Chemotherapy for Oral and Maxillofacial Tumors: An Update | 163 | ||
Key points | 163 | ||
Chemotherapy for early-stage disease | 164 | ||
Chemotherapy for locally advanced resectable disease | 164 | ||
Role of Neoadjuvant Chemotherapy | 164 | ||
Role of Adjuvant Chemotherapy | 164 | ||
Chemotherapy for locally advanced unresectable disease | 164 | ||
Induction Chemotherapy Before Radiation Versus Radiation | 164 | ||
Induction Chemotherapy Before Concurrent Chemoradiation | 165 | ||
Role of Epidermal Growth Factor Inhibitors | 165 | ||
Chemotherapy for metastatic or recurrent disease | 165 | ||
Cytotoxic Chemotherapy | 165 | ||
Targeted Therapy | 166 | ||
Rare tumors | 166 | ||
Osteosarcoma | 166 | ||
Lymphoma | 167 | ||
Giant Cell Tumor of the Jaw | 167 | ||
Summary | 167 | ||
Acknowledgments | 167 | ||
References | 167 | ||
Anti-Resorptive Osteonecrosis of the Jaws | 171 | ||
Key points | 171 | ||
Introduction | 171 | ||
Osteonecrosis of the jaws is seen in patients without cancer who are naive to antiresorptive medications | 172 | ||
Osteonecrosis of the jaws is seen in higher incidences in patients with cancer | 174 | ||
Tori and exostoses are at-risk structures in patients taking antiresorptive medications and in those patients naive to anti ... | 177 | ||
Untreated osteonecrosis of the jaws progresses to more advanced stages | 180 | ||
Resection represents effective and first-line therapy for patients with osteonecrosis of the jaws | 181 | ||
Mandibular segmental defects can be reconstructed in patients exposed to bisphosphonate medications | 184 | ||
Teeth may be extracted in patients exposed to bisphosphonate medications without the subsequent development of osteonecrosis | 186 | ||
Summary | 188 | ||
References | 188 | ||
Oral Surgery in Patients Undergoing Chemoradiation Therapy | 193 | ||
Key points | 193 | ||
Epidemiology | 194 | ||
Chemotherapy | 194 | ||
Radiation therapy | 194 | ||
Preparations before the start of therapy | 195 | ||
The Patient Receiving Chemotherapy | 195 | ||
The Patient Receiving Radiation to the Head and Neck Region | 195 | ||
Patient management during antineoplastic therapy | 198 | ||
Myelosuppression | 198 | ||
Mucositis | 198 | ||
Neurotoxicity and Taste Alteration | 199 | ||
Xerostomia | 200 | ||
After chemotherapy and radiation therapy | 200 | ||
Trismus | 200 | ||
Prevention and treatment of osteonecrosis of the jaw bone | 201 | ||
Oral Surgery in Irradiated Jaws | 202 | ||
Prophylactic Hyperbaric Oxygen Therapy | 202 | ||
ORN: Classification and Treatment | 203 | ||
Dental Implant Placement After Radiation Therapy to the Head and Neck Region | 203 | ||
Summary | 205 | ||
References | 205 | ||
Evaluation and Staging of the Neck in Patients with Malignant Disease | 209 | ||
Key points | 209 | ||
Introduction | 209 | ||
TNM classification and staging | 210 | ||
Considerations for N staging | 211 | ||
Squamous cell carcinoma | 212 | ||
Salivary gland cancers | 213 | ||
Carcinoma of unknown primary | 213 | ||
Evaluation of the neck for nodal metastasis | 214 | ||
Ultrasound | 214 | ||
CT and MRI Evaluation of the Neck | 214 | ||
PET/CT | 216 | ||
Sentinel Lymph Node Biopsy | 217 | ||
Neck Evaluation During Post-therapeutic Surveillance | 217 | ||
References | 218 | ||
Update in Radiation Therapy for Oral and Maxillofacial Tumors and Dose Mapping | 223 | ||
Key points | 223 | ||
Introduction | 223 | ||
Toxicity from RT | 227 | ||
Summary | 228 | ||
References | 228 | ||
The Role of Bisphosphonates in Medical Oncology and Their Association with Jaw Bone Necrosis | 231 | ||
Key points | 231 | ||
The role of bisphosphonates in medical oncology | 231 | ||
Mechanism of Action | 231 | ||
Types of Bisphosphonates | 232 | ||
Administration and Side Effects | 232 | ||
Route of administration | 232 | ||
Side effects | 232 | ||
Absorption and half-life | 232 | ||
Bisphosphonates in Multiple Myeloma | 232 | ||
Bisphosphonates in Solid Tumors | 233 | ||
Bisphosphonates in Metabolic Disorders | 233 | ||
Other Bone-Modifying Agents | 233 | ||
Associated risk of jaw bone necrosis with bisphosphonates | 234 | ||
Pathogenesis | 234 | ||
Acknowledgments | 235 | ||
References | 235 | ||
Nuclear Medicine Imaging Studies in the Diagnosis of Head and Neck Disease | 239 | ||
Key points | 239 | ||
Introduction to PET/CT imaging | 239 | ||
Technical aspects of PET imaging | 241 | ||
Typical images | 242 | ||
PET imaging in DIONJ | 243 | ||
References | 244 | ||
Pharmacologic Modalities in the Treatment of Osteoradionecrosis of the Jaw | 247 | ||
Key points | 247 | ||
Introduction | 247 | ||
Pathogenesis | 247 | ||
Pharmacologic agents in ORN management | 249 | ||
Hyperbaric Oxygen Therapy | 249 | ||
Pentoxifylline and Tocopherol | 250 | ||
Pentoxifylline | 250 | ||
Tocopherol | 250 | ||
Clodronate | 250 | ||
Pentoxifylline and Tocopherol Combined Therapy With or Without Clodronate | 250 | ||
Summary | 251 | ||
References | 252 | ||
Magnetic Resonance Imaging (MRI) in the Diagnosis of Head and Neck Disease | 253 | ||
Key points | 253 | ||
Introduction | 253 | ||
Approach | 253 | ||
Applications | 254 | ||
Neoplasms and Masses | 254 | ||
Infections | 254 | ||
Skull Base and Temporal Bones | 260 | ||
Vascular Lesions | 260 | ||
Brachial Plexus | 267 | ||
Summary | 268 | ||
References | 268 | ||
Index | 271 |